Introduction {#Sec1}
============

Many patients with advanced stage malignancies often develop cachexia. This multifactorial syndrome is associated with both metabolic and endocrine-related effects. Cachexia is characterized by a ≥5 % weight loss, and other symptoms including loss of appetite, energy, muscle mass/strength, and functional performance \[[@CR1], [@CR2]\]. Cachexia can adversely affect a patients' quality of life, their response to therapy, and their survival \[[@CR3]--[@CR6]\].

Ghrelin is a 28-amino acid peptide which acts as the endogenous ligand for the ghrelin receptor (GRLN receptor, formally known as GHS-R1a) \[[@CR7]\]. Administration of ghrelin to animals and humans has been shown to stimulate gastric acid secretion and motility, increase food intake and appetite leading to weight gain, promote anabolic activity, and inhibit production of pro-inflammatory cytokines, and thus may provide a viable target for cancer-related cachexia \[[@CR8]--[@CR11]\]. Ghrelin activity is thought to be mediated by both growth hormone (GH)-dependent and GH-independent mechanisms \[[@CR8]\]. However, the short half-life (∼30 min), and parenteral administration requirement of ghrelin has limited its clinical usefulness, and interest has switched to the development of orally available ghrelin mimetics \[[@CR9]--[@CR11]\]. One of these, anamorelin (ONO-7643, formally known as RC-1291), is a GRLN receptor agonist currently in development for the treatment of non-small-cell lung cancer (NSCLC)-related anorexia and cachexia. Through its ghrelin and GH-releasing activity, anamorelin has both orexigenic and anabolic properties. Anamorelin has been investigated in healthy volunteers and in cancer patients, where it was associated with significant increases in body weight (BW), total and lean body mass, and handgrip strength and improvements in patient-reported symptoms/quality of life assessments. These clinical studies have also shown increases in plasma levels of GH, insulin-like growth factor-1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3) \[[@CR12]--[@CR15]\].

There are conflicting data in the literature regarding the role of ghrelin, GH, and IGF-1 in carcinogenesis. Concerns have been raised that administration of GRLN receptor agonists to cancer patients may potentially stimulate tumor growth. For example, elevated levels of circulating IGF-1 have been observed in cancer patients with certain types of cancers \[[@CR16]\]; however, these increased levels may have originated within the tumor itself, therefore representing a consequence rather than a cause of the tumor \[[@CR17]\]. There have also been conflicting reports on the effects of ghrelin and other GH-stimulating molecules on the growth of tumor cells in vitro (both enhancing and inhibiting tumor cell proliferation and survival). These inconsistencies may be due in part to varying expression of the GRLN receptor, differences between endocrine and non-endocrine tumor cell lines, and variations in testing methods and concentrations of test agents \[[@CR18], [@CR19]\]. Moreover, there have been reports indicating the therapeutic potential of the major binding protein, IGFBP-3, in attenuating oncogenic behavior either via its ability to bind IGF-1 or via direct, IGF-independent actions \[[@CR20]\].

This study was designed to evaluate effects on the growth of A549 NSCLC xenographs in mice administered ghrelin or anamorelin for 28 consecutive days. The plasma levels of GH and IGF-1 were closely monitored in these animals, and potential effects on body weight gain and food consumptions were also measured.

Materials and methods {#Sec2}
=====================

Test agents {#Sec3}
-----------

Ghrelin (Bachem Americas, Inc. Cat \# H-4862, rat/mouse ghrelin) was freshly prepared from pre-weighed vials by dissolving the contents to a concentration of 0.2 mg/mL in saline solution. Anamorelin hydrochloride salt (HCl) (ONO-7643; Helsinn, USA) was formulated in de-ionized (DI) water to a concentration of 3.202 (3 mg/mL free base equivalent) and stored at ambient temperature until use. Additional dosing solutions at 1.07 (1.003 mg/mL free base equivalent) and at 0.32 (0.3 mg/mL free base equivalent) were prepared every 2 weeks by diluting aliquots of the pre-formulated stock solution with DI water.

Mice {#Sec4}
----

Nine- to ten-week-old female athymic nude mice (*nu/nu*, Harlan) with BW ranging from 18.4 to 26.6 g were housed on irradiated bedding in static microisolators under controlled temperature (21--22 °C), humidity (40--60 %), and light/dark cycle (12 h). The animals were given ad libitum water (reverse osmosis, 1 ppm Cl) and NIH 31 Modified and Irradiated Lab Diet® consisting of 18 % crude protein, 5 % crude fat, and 5 % crude fiber. All experimental procedures for animal care and housing were undertaken in an animal care facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and according to the requirements stated in the ILAR Guide for the Care and Use of Laboratory Animals \[[@CR21]\].

Tumor cell culture and implantation {#Sec5}
-----------------------------------

A549 NSCLC tumor cells were grown to mid-log phase in Kaighn's modified Ham's F12 medium supplemented with 10 % fetal bovine serum, 100 units/mL penicillin G, 100 μg/mL streptomycin sulfate, 25 μg/mL gentamicin, 2 mM glutamine, and 1 mM sodium pyruvate. Cell cultures were incubated at 37 °C with 5 % CO~2~ in a humidified atmosphere.

A549 tumor cells used for implantation were harvested during log phase growth and re-suspended in 50 % Matrigel matrix (BD Biosciences) at 5 × 10^7^ cells/mL. Mice were injected subcutaneously in the right flank with a 0.2 mL suspension (1 × 10^7^ cells/mouse).

Treatment study design {#Sec6}
----------------------

In the treatment study (Fig. [1](#Fig1){ref-type="fig"}), implanted tumors were monitored as their volumes approached 150--250 mm^3^. Twenty-one days post-implant (study day 1), mice were randomized into six groups of 15 mice each with individual tumor volumes ranging from 144 to 221 mm^3^ and group mean tumor volumes of 180 mm^3^. Tumor volume in cubic millimeters was calculated using the following formula:$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \mathrm{tumor}\,\mathrm{volume}=\left( {\mathrm{length}\times \mathrm{square}\,\mathrm{of}\,\mathrm{the}\,\mathrm{width}} \right)\div 2 $$\end{document}$. Mice were acclimatized to dosing by administering DI water orally (p.o.) on days 1 and 2, before beginning treatment on day 3. In all groups, the dosing volume of 10 mL/kg was scaled according to the weight of each individual animal. From day 3 to day 30 (28-day treatment period), group 1 received DI water p.o., group 2 received saline intraperitoneally (i.p.), group 3 received ghrelin once daily at 2 mg/kg i.p., and groups 4--6 received anamorelin HCl once daily at 3, 10, or 30 mg/kg p.o.Fig. 1Study design

Sampling study design {#Sec7}
---------------------

In the sampling study (Fig. [1](#Fig1){ref-type="fig"}), mice with implanted tumors were monitored until 21 days post-implant (study day 1) and randomized into three groups of 21 mice each with individual BW ranging from 19.1 to 26.3 g and a group mean of 22.7--23.0 g. Acclimatizing with DI water and scaling dosing volume followed the same procedures as for the treatment study. In the sampling study, from days 3 to 30 (28-day treatment period), group 1 received DI water p.o., group 2 received ghrelin once daily at 2 mg/kg i.p., and group 3 received anamorelin HCl once daily at 30 mg/kg p.o.

Endpoints {#Sec8}
---------

In the treatment study, tumor volumes were measured twice-weekly until study completion on day 30, and mean tumor volumes and median tumor volumes (MTV) were calculated for each group. Tumor growth inhibition (TGI) was calculated for each group according to the following formula: $\documentclass[12pt]{minimal}
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                \begin{document}$$ \%\mathrm{TGI}=\left[ {\left( {\mathrm{MT}{{\mathrm{V}}_{\mathrm{control}}}-\mathrm{MT}{{\mathrm{V}}_{\mathrm{treated}}}} \right)\div \mathrm{MT}{{\mathrm{V}}_{\mathrm{control}}}} \right]\times 100 $$\end{document}$. Food consumption was measured daily, with mean daily food consumption calculated as the difference between the food weight before and after the feeding period for each group. Animals were weighed daily, and the mean BW on days 3, 15, and 30 were calculated. Percentage change in BW from days 3 to 30 was determined for each group.

In the sampling study, whole blood samples from three animals in each group were obtained by retro-orbital bleed under isoflurane anesthesia into ethylenediaminetetraacetic acid-coated tubes. Samples were taken prior to the first dose and at 5, 15, 30, 60, 180, and 360 min after the first and last doses of DI water, ghrelin 2 mg/kg, and anamorelin 30 mg/kg. Murine insulin-like growth factor-1 (mIGF-1) and murine growth hormone (mGH) were assessed from plasma samples using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Assays with rat/mouse IGF-1 ELISA kits (Immunodiagnostic Systems, Cat. No. AC-18 F1) and rat/mouse GH ELISA kits (Millipore Corporation, Cat. No. EZRMGH-45 K) were performed as per manufacturer's instructions. Results were expressed as means ± standard error of the mean.

Toxicity {#Sec9}
--------

In both studies, mice were observed frequently for signs of any adverse treatment-related side effects, and clinical signs of toxicity were recorded. Acceptable toxicity for the maximum tolerated dose was defined as a group mean BW loss of less than 20 % and not more than 10 % treatment-related mortality. Relationship to treatment was determined by signs and/or necropsy, or due to unknown causes during the dosing period.

Statistical analysis {#Sec10}
--------------------

Data analysis was performed using Prism software, version 3.03 (GraphPad). Statistical analyses of the differences between the median tumor burdens and percentage change in BW in control and treated groups were calculated using the Kruskal--Wallis or Mann--Whitney *U* test. Differences in BW and cumulative food consumption for each group compared with control were assessed using one-way analysis of variance or unpaired *t* test. All analyses were assessed at a significance level of 0.05.

Results {#Sec11}
=======

Effects of ghrelin and anamorelin on tumor growth in vivo {#Sec12}
---------------------------------------------------------

Tumor growth progressed steadily over time in all groups, with no statistically significant differences between the ghrelin- and anamorelin-treated animals and their respective controls (Fig. [2](#Fig2){ref-type="fig"}). Animals administered anamorelin at 10 mg/kg, but not 30 mg/kg, had a delay in their median tumor growth curve compared with their control group, therefore, this difference was not drug-related.Fig. 2Effect of treatment on median tumor volume over time

Day 30 MTV and percentage TGI data are presented in Table [1](#Tab1){ref-type="table"}.Table 1Tumor growth inhibition on day 30Treatment groupMTV, mm^3^%TGIIndividual tumor volume range^a^, mm^3^1: DI water p.o.1,008--446--1,6662: Saline i.p.968--221--2,0253: Ghrelin i.p. 2 mg/kg9363256--1,6884: Anamorelin p.o. 3 mg/kg1,080−7245--2,1765: Anamorelin p.o. 10 mg/kg66634126--1,6666: Anamorelin p.o. 30 mg/kg84716320--2,432*DI* deionized, *i.p.* intraperitoneal, *MTV* median tumor volume, *p.o*. oral, *TGI* tumor growth inhibitionDI water (group 1) is the designated control group for groups 4--6; saline (group 2) is the designated control group for group 3. Comparisons of treatment groups versus their respective controls were not statistically significant (*p* \> 0.05)^a^Range = minimum − maximum for the 15 individual animals per treatment group

Effects of ghrelin and anamorelin on food consumption and body weight {#Sec13}
---------------------------------------------------------------------

Median daily food consumption was similar in all groups, unchanged over the course of the study, and without any statistically significant difference between groups (Fig. [3](#Fig3){ref-type="fig"}). Animals administered 30 mg/kg of anamorelin showed a trend of increased food intake compared with their controls, but the increase was not statistically significant.Fig. 3Effect of treatment on median daily feed consumption over time

Figure [4](#Fig4){ref-type="fig"} shows the percentage change in mean BW over time. In animals administered ghrelin 2 mg/kg, the percentage change in mean BW from days 1 to 30 was greater compared with the saline control group (13.7 % ± 1.55 versus 10.5 % ± 1.04, respectively). However, this difference was not statistically significant. Over the treatment period, animals administered anamorelin at 10 and 30 mg/kg/day showed a statistically significant increase in their percentage of mean BW (11.7 % ± 1.26 and 14.4 % ± 1.08, respectively) compared with controls (7.6 % ± 0.99; *p* \< 0.01 versus 10 mg/kg and *p* \< 0.001 versus 30 mg/kg). Mice administered 3 mg/kg anamorelin did not show a statistically significant increase in BW compared with control animals (9.1 % ± 0.97; *p \>* 0.05).Fig. 4Effect of treatment on percentage change in mean body weight over time. Error bars have been omitted for clarity

Effects of ghrelin and anamorelin on plasma levels of mIGF-1 and mGH {#Sec14}
--------------------------------------------------------------------

Compared with the vehicle control, peak plasma levels of mIGF-1 were higher in animals administered ghrelin 2 mg/kg and anamorelin 30 mg/kg compared with controls, but this difference was not statistically significant (Fig. [5a](#Fig5){ref-type="fig"}). The plasma levels of mIGF-1 in response to DI water and ghrelin exhibited peak values of 554 ± 25.13 and 647.1 ± 11.63 ng/mL, respectively, at 15 min after the last dose. The plasma levels of mIGF-1 in response to anamorelin exhibited peak values of 713.2 ± 50.08 ng/mL at 5 min after the last dose.Fig. 5Plasma levels of mIGF-1 (**a**) and mGH (**b**) after the last dose

Peak plasma levels of mGH in animals administered anamorelin 30 mg/kg and ghrelin 2 mg/kg were greater than the controls at 5--30 min after the last dose (Fig. [5b](#Fig5){ref-type="fig"}). The plasma levels of mGH in response to DI water exhibited peak values of 21.4 ± 6.53 ng/mL at 15 min after the last dose. The plasma levels of mGH in response to ghrelin peaked at 1,318.9 ± 173.59 ng/mL at 15 min after the last dose, and the plasma level of mGH in response to anamorelin peaked at 64.9 ± 12.73 ng/mL at 15 min after the last dose.

Toxicity {#Sec15}
--------

There were no signs of drug-related toxicity and no treatment-related deaths.

Discussion {#Sec16}
==========

In this study, our primary objectives were to evaluate the effects of anamorelin or ghrelin treatment on the growth of A549 NSCLC xenografts and to measure GH and IGF-1 plasma concentrations. Additional objectives included the effects of daily treatment with ghrelin or anamorelin on food consumption, BW changes, and potential toxicity in this model.

Overall, our results show that all regimens were well tolerated with no treatment-related deaths and no observations indicative of treatment-related side effects. Most importantly, neither ghrelin nor anamorelin treatment for 28 days affected tumor growth in tumor-bearing nude mice, despite significantly increased peak mGH levels and slight elevations in peak mIGF-1 levels. Specifically, anamorelin stimulated a maximum increase in GH concentrations by up to ∼2.5-fold after repeated administration, which is similar to previously published data with MK677 (another GRLN receptor agonist) in dogs \[[@CR22]\], while repeated dosing with ghrelin in this study resulted in a maximum increase in GH concentrations of approximately 50-fold. For IGF-1, the average mean concentration after the last dose of anamorelin was increased up to 122 % of the vehicle-treated animals, and ghrelin's post-last-dose IGF-1 concentration was 109 % of the vehicle-treated animals.

The finding in our study that ghrelin and anamorelin do not promote tumor growth, even in the presence of elevated GH and IGF-1, is consistent with findings from other studies evaluating GH-based therapies in tumor-bearing animals \[[@CR9], [@CR23]--[@CR26]\], as well as in formal carcinogenicity studies in tumor-free animals \[[@CR27]\], as summarized below.

In a study by Khan et al. \[[@CR9]\], treatment with a GH-releasing hormone (GHRH)-expressing plasmid in nude mice implanted with a human bronchioalveolar carcinoma cell line did not increase the growth of the tumor, but rather it reduced tumor volume by 40 %, suggesting that the therapeutic role of GH-based therapies may not be limited to cachexia. Similarly, constitutive expression of GHRH in an immunocompetent animal model led to a decrease in tumor growth rate and additionally reduced the likelihood of metastasis \[[@CR23]\], whereas immunocompetent mice pre-treated with an analog of MK677 resisted subsequent tumor initiation \[[@CR24]\]. Perboni et al. demonstrated that the addition of the ghrelin agonist growth hormone releasing peptide-2 (GHRP-2) to cytotoxic therapy with 5-fluorouracil (5-FU) prevented the anorexia associated with chemotherapy in tumor-bearing cachectic BALB/c mice, and there was also a trend of improved survival in the 5-FU + GHRP-2 treated mice compared with those with 5-FU alone \[[@CR25]\]. Infusion of a ghrelin analog (BIM-28131) or human ghrelin in a rat sarcoma model also demonstrated beneficial anti-cachexia effects (improved food consumption, BW, and retention of lean body mass), and there was no increase in tumor mass after treatment \[[@CR26]\]. In terms of GH safety in tumor-free animals, Farris et al. conducted a formal 2-year bioassay in rats and mice to investigate the carcinogenic potential of each biologically active GH in the respective species \[[@CR27]\]. Recombinant rat and mouse GH administration resulted in systemic GH exposures of approximately 10-fold over basal levels. Even in the presence of these elevated GH levels, there were no increases in incidence or spectrum of neoplastic changes in either species, and there was a favorable effect on longevity. There were also no treatment-related physical signs noted in either species or gender, and all doses were well tolerated \[[@CR27]\].

There is also experimental evidence in cancer cachexia that suggests IGF-1 might be beneficial rather than harmful. For example, in rats bearing the AH-130 hepatoma, a well-characterized model of cachexia, the expression of IGF-1 in liver and skeletal muscle was shown to be reduced compared with controls \[[@CR28]\]. Furthermore, in the Yoshida hepatoma rat model, Schmidt et al. showed that low-dose IGF-1 supplementation had no effect on tumor growth and actually reduced mortality. Moreover, there was an attenuated loss of BW and muscle mass, and an improved quality of life was observed in IGF-1-treated animals \[[@CR29]\]. These data highlight the need for more studies to elucidate the interactions of IGF-1 on tumor growth and on cancer-related cachexia.

From a clinical perspective, data obtained to-date with anamorelin also support the safety profile in human cancer patients. For example, in a Phase II study with over 80 patients with different tumor types, there was no difference in the incidence of adverse events of "disease progression" between patients receiving placebo or anamorelin for up to 12 weeks \[[@CR15]\]. Currently, anamorelin is being evaluated in two Phase III clinical trials in cachectic patients with advanced NSCLC ([NCT01387269](http://www.clinicaltrials.gov/NCT01387269) and [NCT01387282](http://www.clinicaltrials.gov/NCT01387282)), and the 12-week safety extension study ([NCT01395914](http://www.clinicaltrials.gov/NCT01395914)) may provide additional support of the long-term safety of anamorelin in cancer patients.

In conclusion, the findings from this study support the development of GRLN receptor agonist treatments for the management of NSCLC-related anorexia/cachexia. Importantly, neither ghrelin nor anamorelin promoted tumor growth in this murine xenograft model, and anamorelin also demonstrated its ability to significantly increase BW. Additional studies in other experimental tumor models, as well as evaluations of IGFBP-3 levels, may help to further understand the interactions between ghrelin, ghrelin mimetics, and the additional effects of increased GH and IGF-1 plasma levels on the growth of tumor cells in vivo.
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